WO 200153312 Comparison.

ID AAM38741 standard; Protein; 772 AA.
XX
AC AAM38741;
XX
DT 22-OCT-2001 (first entry)
XX
DE Human polypeptide SEQ ID NO 2926.
XX
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia.
XX
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001.
XX
PF 26-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0653450.
PR 14-SEP-2000; 2000US-0662191.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR N-PSDB; AAI58937.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Example 4; SEQ ID NO 2926; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic

CC and thrombolytic activity, cancer diagnosis and therapy, drug screening, CC assays for receptor activity, arthritis and inflammation, leukaemias and CC C.N.S disorders.
CC Note: The sequence data for this patent did not form part of the printed CC specification.
XX
SQ Sequence 772 AA;

Query Match 100.0%; Score 4037; DB 22; Length 772;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 772; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

```
Qy       1 MRLSSLLALLRPALPLILGLSLGGSLSLLRVSWIQGEGEDPGVEAVGERGGPQNPDSPAR 60
Db       1 mrlssllallrpalplilglslggslsllrvswiqgegedpgveavgerggpqnpdspar 60

Qy      61 LDQSDEDFKPRIVPYYRDPNKPYKKVLRTRYIQTELGSRERLLVAVLTSRATLSTLAVAV 120
Db      61 ldqsdedfkprivpyyrdpnkpykkvlrtryiqtelgsrerllvavltsratlstlavav 120

Qy     121 NPTVAHHFPRLLYFTGQPGARAPAGMQVVSHGDEPPAWLMSETLRHLHTHFGADYDWFFI 180
Db     121 nptvahhfprllyftgqpgarapagmqvvshgderpawlmsetlrhlhthfgadydwffi 180

Qy     181 MQDNTYVQAPPLAALAGHLSINQDLYLGPAEEFIGAGEQAPYCHGGPGYLLSRSLLLPLR 240
Db     181 mqddtyvqaprlaalaghlsinqdlylgpaeefigageqaprychggpgyllsrslllplr 240

Qy     241 PHLDGCRGDILSAPPDEWLGRCLIDSLGVGCVSQHQGQQYRSFELAKNRDPEKEGSSAFL 300
Db     241 phldgcrgdilsappdewlgrclidslgvgcvsqhqgqqyrsfelaknrdpekegssafl 300

Qy     301 SAPAVHPVSEGTLMYRLHKRPSALELERAYSEIEQLQAQIRNLTVLTPEGEAGLSWPVGL 360
Db     301 sapavhpvsegtlmyrlhkrpsalelerayseieqlqaqirnltvltpegeaglswpvgl 360

Qy     361 PAPFTPHSRFEVLGWDYFTEQHTFSCADGAPKCPLQGASRADVGDALETALEQLNRRYQP 420
Db     361 papftphsrfevlgwdyfteqhtfscadgapkcplqgasradvgdaletaleqlnrryqp 420

Qy     421 PLREQKQPLLNGYRRFDPARGMEYTLDLLLECVTQRGHRRALARRVSLLRPLSRVEILPM 480
Db     421 rlrfqkqpllngyrrfdpargmeytldlllecvtqrghrralarrvsllrplsrveilpm 480

Qy     481 PYVTEATRVQIVIPLLVAEAAAAPAFLEAPAANVLEPPEHALLTLLLVYGPKEGGRGAPD 540
Db     481 pyvteatrvqlvlpllvaeaaaapafleapaanvlepprehalltlllvygpkeggrgapd 540

Qy     541 PFLGVKAAAAELERRYPGTPLAWLAVRAEAPSQVRLMDVVSKKHPVDTLFFLTTVWTRPG 600
Db     541 pflgvkaaaaelerrypgtplawlavraeapsqvrlmdvvskkhpvdtlfflttvwtrpg 600

Qy     601 PEVLNRCRMNAISGWQAFFPVHFQEFNPALSPQRSPPGPPGAGPDPPSPPGADPSRGAPI 660
Db     601 pevlnrcrmnaisgwqaffpvhfqefnpalspqrsppgppgagpdppsppgadpsrgapi 660
```

```
Qy     661 GGRFDRQASAEGCFYNADYLAARARLAGELAGQEEEEALEGLEVMDVFLRFSGLHLFRAV 720
           ||||||||||| ||||| |||||||||||||||||||||||||||||||||||||||||
Db     661 ggrfdrqasaegcfynadylaararlagelagqeeeealeglevmdvflrfsglhlfrav 720

Qy     721 EPGLVQKFSLRDCSPRLSEELYHRCRLSNLEGLGGRAQLAMALFEQEQANST 772
           ||||||||||||||||||||||||||||||||||||||||||||||||||||
Db     721 epglvqkfslrdcsprlseelyhrcrlsnleglggraqlamalfeqeqanst 772
```

```
RESULT 2
AAB80269
ID   AAB80269 standard; Protein; 772 AA.
XX
AC   AAB80269;
XX
DT   24-APR-2001  (first entry)
XX
DE   Human PRO339 protein.
XX
KW   Human; PRO; dermatological; antipsoriatic; cytostatic; antiinflammatory;
KW   antiparkinsonian nootropic; neuroprotective; vulnerary; cardiant;
KW   antiangiogenic; vasotropic; antiasthmatic; antirheumatic; cancer;
KW   antiarthritic; antiinfertility; antidiabetic; antiviral; diabetes;
KW   ophthalmological; gene therapy; skin disease; gastrointestinal disorder;
KW   ischaemia; inflammation.
XX
OS   Homo sapiens.
XX
PN   WO200104311-A1.
XX
PD   18-JAN-2001.
XX
PF   22-FEB-2000; 2000WO-US04414.
XX
PR   07-JUL-1999;   99US-0143048.
PR   26-JUL-1999;   99US-0145698.
PR   28-JUL-1999;   99US-0146222.
PR   08-SEP-1999;   99WO-US20594.
PR   13-SEP-1999;   99WO-US20944.
PR   15-SEP-1999;   99WO-US21090.
PR   15-SEP-1999;   99WO-US21547.
PR   05-OCT-1999;   99WO-US23089.
PR   29-NOV-1999;   99WO-US28214.
PR   30-NOV-1999;   99WO-US28313.
PR   16-DEC-1999;   99WO-US30095.
PR   20-DEC-1999;   99WO-US30911.
PR   20-DEC-1999;   99WO-US30999.
PR   05-JAN-2000;   99WO-US00219.
XX
PA   (GETH ) GENENTECH INC.
XX
PI   Ashkenazi AJ,  Botstein D,  Desnoyers L,  Eaton DL,  Ferrara N;
PI   Filvaroff E,  Fong S,  Gao W,  Gerber H,  Gerritsen ME,  Goddard A;
PI   Godowski PJ,  Grimaldi CJ,  Gurney AL,  Hillan KJ,  Kljavin IJ;
PI   Mather JP,  Pan J,  Paoni NF,  Roy MA,  Stewart TA,  Tumas D;
PI   Williams PM,  Wood WI;
XX
```

ID AAI57947 standard; cDNA; 2710 BP.
AC AAI57947;
DT 22-OCT-2001 (first entry)
DE Human polynucleotide SEQ ID NO 1140.
KW Human; nootropic; immunosuppressant; cytostatic; gene therapy; cancer;
KW peripheral nervous system; neuropathy; central nervous system; CNS;
KW Alzheimer's; Parkinson's disease; Huntington's disease; haemostatic;
KW amyotrophic lateral sclerosis; Shy-Drager Syndrome; chemotactic;
KW chemokinetic; thrombolytic; drug screening; arthritis; inflammation;
KW leukaemia; CNS.
OS Homo sapiens.
XX
PN WO200153312-A1.
XX
PD 26-JUL-2001
XX
PF 20-DEC-2000; 2000WO-US34263.
XX
PR 21-JAN-2000; 2000US-0488725.
PR 25-APR-2000; 2000US-0552317.
PR 09-JUL-2000; 2000US-0598042.
PR 19-JUL-2000; 2000US-0620312.
PR 03-AUG-2000; 2000US-0633450.
PR 14-SEP-2000; 2000US-0662192.
PR 19-OCT-2000; 2000US-0693036.
PR 29-NOV-2000; 2000US-0727344.
XX
PA (HYSE-) HYSEQ INC.
XX
PI Tang YT, Liu C, Asundi V, Chen R, Ma Y, Qian XB, Ren F, Wang D;
PI Wang J, Wang Z, Wehrman T, Xu C, Xue AJ, Yang Y, Zhang J;
PI Zhao QA, Zhou P, Goodrich R, Drmanac RT;
XX
DR WPI; 2001-442253/47.
DR P-PSDB; AAM39781.
XX
PT Novel nucleic acids and polypeptides, useful for treating disorders
PT such as central nervous system injuries -
XX
PS Claim 1; SEQ ID NO 1140; 10078pp; English.
XX
CC The invention relates to human nucleic acids (AAI57798-AAI61369) and
CC the encoded polypeptides (AAM38642-AAM42213) with nootropic,
CC immunosuppressant and cytostatic activity. The polynucleotides are useful
CC in gene therapy. A composition containing a polypeptide or polynucleotide
CC of the invention may be used to treat diseases of the peripheral nervous
CC system, such as peripheral nervous injuries, peripheral neuropathy and
CC localised neuropathies and central nervous system diseases, such as
CC Alzheimer's, Parkinson's disease, Huntington's disease, amyotrophic
CC lateral sclerosis, and Shy-Drager Syndrome. Other uses include the
CC utilisation of the activities such as: Immune system suppression,
CC Activin/inhibin activity, chemotactic/chemokinetic activity, haemostatic
CC and thrombolytic activity, cancer diagnosis and therapy, drug screening,
CC assays for receptor activity, arthritis and inflammation, leukaemias and
CC C.N.S disorders.
CC Note The sequence data for this patent did not form part of the printed
CC specification.
XX
SQ Sequence 2710 BP; 506 A; 821 C; 824 G; 559 T; 0 other;

Query Match 96.5%; Score 2692; DB 22; Length 2710;
Best Local Similarity 100.0%; Pred. No. 0;
Matches 2092; Conservative 0; Mismatches 0; Indels 0; Gaps 0;

Qy 98 ggggttagttccgacaccttcacagttgaagagcaggcagaaaggagttgtgaagacagg 157